A Clinical Study to Evaluate the Safety and Efficacy of ESO-T01 in Treating Relapsed/Refractory Multiple Myeloma.

This study is testing a new CAR-T cell therapy called ESO-T01 for people with relapsed or refractory multiple myeloma — a blood cancer affecting plasma cells in the bone marrow — that has come back or stopped responding to multiple prior treatments. ESO-T01 targets a protein called BCMA that is commonly found on myeloma cells. **You may be eligible if...** - You are 18 or older - You have confirmed multiple myeloma with BCMA expression on your cancer cells - You have received at least 2 prior lines of treatment, including both an immunomodulatory drug and a proteasome inhibitor, and your cancer has progressed - Your disease is measurable on standard tests **You may NOT be eligible if...** - You have not received enough prior treatments (less than 2 prior lines) - You have active serious infections (such as uncontrolled HIV, hepatitis B or C) - You have significant heart, lung, liver, or kidney problems - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.